AR073905A1 - Ligandos que tienen especificidad de union por dc-sign - Google Patents
Ligandos que tienen especificidad de union por dc-signInfo
- Publication number
- AR073905A1 AR073905A1 ARP090104011A ARP090104011A AR073905A1 AR 073905 A1 AR073905 A1 AR 073905A1 AR P090104011 A ARP090104011 A AR P090104011A AR P090104011 A ARP090104011 A AR P090104011A AR 073905 A1 AR073905 A1 AR 073905A1
- Authority
- AR
- Argentina
- Prior art keywords
- sign
- links
- compositions
- immunoglobulin
- union
- Prior art date
Links
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 title abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 3
- 102000018358 immunoglobulin Human genes 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 abstract 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10708508P | 2008-10-21 | 2008-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073905A1 true AR073905A1 (es) | 2010-12-09 |
Family
ID=42062429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104011A AR073905A1 (es) | 2008-10-21 | 2009-10-19 | Ligandos que tienen especificidad de union por dc-sign |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110257373A1 (enExample) |
| EP (1) | EP2356149A2 (enExample) |
| JP (1) | JP2012506237A (enExample) |
| KR (1) | KR20110071139A (enExample) |
| CN (1) | CN102257009A (enExample) |
| AR (1) | AR073905A1 (enExample) |
| AU (1) | AU2009306424A1 (enExample) |
| BR (1) | BRPI0919714A2 (enExample) |
| CA (1) | CA2740856A1 (enExample) |
| EA (1) | EA201100488A1 (enExample) |
| IL (1) | IL212086A0 (enExample) |
| MX (1) | MX2011004244A (enExample) |
| TW (1) | TW201019962A (enExample) |
| UY (1) | UY32189A (enExample) |
| WO (1) | WO2010046337A2 (enExample) |
| ZA (1) | ZA201102763B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009306425B2 (en) * | 2008-10-21 | 2013-09-12 | Domantis Limited | Composition for targeting dendritic cells |
| WO2013095973A1 (en) * | 2011-12-19 | 2013-06-27 | The Rockefeller University | Hdc-sign binding peptides |
| US20250319024A1 (en) * | 2021-08-27 | 2025-10-16 | University Of Georgia Research Foundation, Inc. | Targeted nanoparticles and their uses related to infectious disease |
| CN118184795B (zh) * | 2022-12-13 | 2025-03-21 | 成都维瑾柏鳌生物医药科技有限公司 | 抗hiv-1的重组蛋白及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0598108A1 (en) * | 1992-06-05 | 1994-05-25 | Dade Produktions AG | Rabbit single domain antibody and use thereof |
| EP2284192A3 (en) * | 2002-11-08 | 2011-07-20 | Ablynx N.V. | Camelidae antibodies for sublingual administration |
| RU2357974C2 (ru) * | 2003-01-10 | 2009-06-10 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| JP4889493B2 (ja) * | 2003-05-14 | 2012-03-07 | ドマンティス リミテッド | ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法 |
| ES2315664T3 (es) * | 2003-06-30 | 2009-04-01 | Domantis Limited | Anticuerpos de dominio unico (dab) pegilados. |
| JP4970035B2 (ja) * | 2003-08-21 | 2012-07-04 | リポテック・プロプライエタリー・リミテッド | ｉｎｖｉｖｏにおける樹状細胞の標的化 |
| CA2569240A1 (en) * | 2004-06-01 | 2005-12-15 | Domantis Limited | Drug fusion comprising a polypeptide drug and an immunoglobulin heavy chain variable domain specific for serum albumin |
| JP2008521870A (ja) * | 2004-12-02 | 2008-06-26 | ドマンティス リミテッド | 抗ｉｌ−１ｒ１単一ドメイン抗体および治療使用 |
| WO2006059106A2 (en) * | 2004-12-02 | 2006-06-08 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
| KR20080003351A (ko) * | 2005-03-18 | 2008-01-07 | 도만티스 리미티드 | 캔디다 항원에 대한 항체 |
| US20100056439A1 (en) * | 2005-12-06 | 2010-03-04 | Domantis Limited | Ligands that have binding specificity for egfr and/or vegf and methods of use therefor |
| CA2632424A1 (en) * | 2005-12-06 | 2007-06-14 | Domantis Limited | Bispecific ligands with binding specificity to cell surface targets and methods of use therefor |
| TW200804593A (en) * | 2006-01-24 | 2008-01-16 | Domantis Ltd | Fusion proteins that contain natural junctions |
| WO2008039432A1 (en) * | 2006-09-26 | 2008-04-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for enhancing an adjuvant |
| WO2008070363A2 (en) * | 2006-10-31 | 2008-06-12 | Domantis Limited | Intrabodies |
| CN101182539A (zh) * | 2007-11-06 | 2008-05-21 | 浙江大学 | Dc-sign启动子荧光素酶报告质粒的构建方法 |
-
2009
- 2009-10-19 KR KR1020117011399A patent/KR20110071139A/ko not_active Withdrawn
- 2009-10-19 CA CA2740856A patent/CA2740856A1/en not_active Abandoned
- 2009-10-19 EA EA201100488A patent/EA201100488A1/ru unknown
- 2009-10-19 BR BRPI0919714A patent/BRPI0919714A2/pt not_active IP Right Cessation
- 2009-10-19 WO PCT/EP2009/063655 patent/WO2010046337A2/en not_active Ceased
- 2009-10-19 TW TW098135298A patent/TW201019962A/zh unknown
- 2009-10-19 US US13/125,384 patent/US20110257373A1/en not_active Abandoned
- 2009-10-19 CN CN2009801529594A patent/CN102257009A/zh active Pending
- 2009-10-19 MX MX2011004244A patent/MX2011004244A/es not_active Application Discontinuation
- 2009-10-19 AR ARP090104011A patent/AR073905A1/es not_active Application Discontinuation
- 2009-10-19 JP JP2011531514A patent/JP2012506237A/ja active Pending
- 2009-10-19 EP EP09736603A patent/EP2356149A2/en not_active Withdrawn
- 2009-10-19 AU AU2009306424A patent/AU2009306424A1/en not_active Abandoned
- 2009-10-20 UY UY0001032189A patent/UY32189A/es unknown
-
2011
- 2011-04-03 IL IL212086A patent/IL212086A0/en unknown
- 2011-04-13 ZA ZA2011/02763A patent/ZA201102763B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201100488A1 (ru) | 2011-12-30 |
| MX2011004244A (es) | 2011-05-25 |
| CN102257009A (zh) | 2011-11-23 |
| BRPI0919714A2 (pt) | 2015-12-08 |
| KR20110071139A (ko) | 2011-06-28 |
| IL212086A0 (en) | 2011-06-30 |
| US20110257373A1 (en) | 2011-10-20 |
| CA2740856A1 (en) | 2010-04-29 |
| WO2010046337A2 (en) | 2010-04-29 |
| ZA201102763B (en) | 2012-09-26 |
| JP2012506237A (ja) | 2012-03-15 |
| UY32189A (es) | 2010-05-31 |
| WO2010046337A3 (en) | 2010-07-01 |
| EP2356149A2 (en) | 2011-08-17 |
| TW201019962A (en) | 2010-06-01 |
| AU2009306424A1 (en) | 2010-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015001507A1 (es) | Proteínas de unión al antígeno bcma | |
| RU2014136702A (ru) | Одноцепочечные антитела и другие гетеромультимеры | |
| CO6571853A2 (es) | Composiciones catalizadoras de metaloceno heteronuclear nano - enlazado y sus productos polímericos | |
| UA114707C2 (uk) | БІСПЕЦИФІЧНА ЗВ'ЯЗУВАЛЬНА МОЛЕКУЛА, ЯКА ЗВ'ЯЗУЄТЬСЯ З VEGF I Ang2 | |
| BR112012023015A2 (pt) | imunoensaios para lenalidomida e talidomida | |
| CY1122978T1 (el) | Αντισωματα εναντι-vla-4 | |
| EA201590209A1 (ru) | Применение cart19 для истощения нормальных b-клеток для индукции толерантности | |
| MX372849B (es) | Partículas conjugadas con péptidos. | |
| UA112416C2 (uk) | Антитіло до fap і способи його застосування | |
| TR201820837T4 (tr) | Natalizumab antikor formülasyonları. | |
| ECSP099688A (es) | Moléculas y métodos para modular la pro-proteína | |
| EA201390847A1 (ru) | Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований | |
| UA116632C2 (uk) | Химерний білок, який містить фактор viii та фактор віллебранда, і його застосування | |
| EA201491573A1 (ru) | Применение передающего сигнал домена cd2 в химерных антигенспецифических рецепторах второго поколения | |
| TN2010000169A1 (en) | Molecules and methods for modulating complement component | |
| JO3118B1 (ar) | تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة | |
| MY172156A (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| BR112014019611A2 (pt) | agentes de ligação mica | |
| UY35063A (es) | Composiciones y métodos que se dirigen a células estromales para el tratamiento del cáncer | |
| IN2012DN00640A (enExample) | ||
| MX342034B (es) | Proteinas monovalentes que se unen a antigenos. | |
| MX2021000306A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno y fc modificados genéticamente dirigidos a ctla-4. | |
| AR073905A1 (es) | Ligandos que tienen especificidad de union por dc-sign | |
| MX2021000287A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
| MX2021000307A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |